FAST NEWS: Everest Medicines gets new drug license from Kezar Life
The latest: Everest Medicines Ltd. (1952.HK) announced Thursday that it has received an exclusive license from Kezar Life Sciences (KZR.US) to develop, manufacture and commercialize Zetomipzomib, a treatment for autoimmune diseases,…
Recent Articles
RECENT ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
